Leadman(SZ:300289) 智通财经网·2025-07-30 14:01Core Viewpoint - Company is planning to acquire up to 70% of Beijing Xiansheng Xiangrui Biological Products Co., Ltd. through cash payment, aiming to gain control over the target company, which will become a subsidiary after the transaction is completed [1] Group 1: Transaction Details - The funding for the acquisition will come from the company's own funds and bank merger loans [1] - Prior to the transaction, the company did not hold any shares in the target company [1] - The investment framework agreement has been signed with the target company and its shareholders [1] Group 2: Target Company Overview - The target company operates in the biopharmaceutical manufacturing industry (C2761) [1] - It specializes in in vitro diagnostic reagents and human vaccines, with key products including purified protein derivative for tuberculosis and specific immune response detection kits [1] - The main applications of the target company's products are in tuberculosis screening, diagnosis, treatment, and innovative vaccine development [1] Group 3: Strategic Implications - Upon completion of the acquisition, the company's IVD (in vitro diagnostics) business segment will expand to include tuberculosis diagnostic screening and integrated treatment business, as well as innovative vaccine initiatives [1]